CEACAM-6

CEACAM-6

CEACAM-6 Overview

Molecule Name
Carcinoembryonic antigen related cell adhesion molecule 6
Synonyms
CEACAM6,CD66c,CEAL,NCA
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
CEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
Background
Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

CEACAM-6 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NEO-201NEO-201Phase 2 ClinicalNational Cancer Institute, Precision Biologics Inc
Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
EBC-129EBC129; EBC-129Phase 1 ClinicalExperimental Drug Development Centre
Solid tumours
Details
DNP-002DNP-002Phase 1 ClinicalDinona
Solid tumours
Details